Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   12/09/2025
141,87 USD (-1,20%)
(-1,20%)   12/09/2025

26 augustus 2025 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in September · Persbericht

6 augustus 2025 · Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference · Persbericht

30 juli 2025 · Neurocrine Biosciences Reports Second Quarter 2025 Financial Results · Persbericht

15 juli 2025 · Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition · Persbericht

15 juli 2025 · Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 · Persbericht

14 juli 2025 · Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting · Persbericht

14 juli 2025 · Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 · Persbericht

9 juli 2025 · Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results · Persbericht

30 juni 2025 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist · Persbericht

27 juni 2025 · Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea · Persbericht

20 juni 2025 · Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia · Persbericht

9 juni 2025 · Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer · Persbericht

2 juni 2025 · Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia · Persbericht

28 mei 2025 · Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 · Persbericht

16 mei 2025 · Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting · Persbericht

16 mei 2025 · Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia · Persbericht

15 mei 2025 · Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont) · Persbericht

14 mei 2025 · Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia · Persbericht

8 mei 2025 · Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups · Persbericht

6 mei 2025 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in May · Persbericht

Mijn selecties